Navigation Links
Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
Date:6/19/2013

are gone. The estimated median response duration was 17.5 months. The median progression free survival was 13.9 months and while the median overall survival for this study has not yet been reached it is estimated to be 58 percent at 18 months. The overall response to ibrutinib was independent of prior treatment including bortezomib and lenalidomide or underlying risk/prognosis, bulky disease, gender or age. In an initial subset of patients enrolled in the study who have the longest follow up (n=51), the response to ibrutinib increased with longer duration of treatment, with the complete response rate increasing from 16 percent at a median follow-up of 3.7 months to 37 percent at a median follow-up of 18.2 months.

The majority of adverse events (AEs) were Grade 1 or 2 in severity, with the most common AEs attributed to ibrutinib being diarrhea, infections and fatigue. Only 7 percent of patients irrespective of relationship experienced an AE leading to treatment discontinuation. Grade 3-4 hematological toxicities were infrequent, with neutropenia (16 percent), thrombocytopenia (11 percent) and anemia (10 percent) as the most frequent hematological AEs reported.

Data from this study were presented at the annual meeting of the American Society of Hematology in December 2012, the European Hematology Association annual meeting in June 2013 and are being presented at the 12th International Conference on Malignant Lymphoma in Lugano, Switzerland this week.

Study Design
The Phase 2, open-label, multicenter study was designed to determine the safety and efficacy of ibrutinib in patients with relapsed or refractory MCL. The primary endpoint of the study was overall response rate. Secondary endpoints included: duration of response, progression free survival, overall survival and frequency and severity of adverse events.

The study enrolled patients with a confirmed diagnosis of relapsed or refractory MCL at 18 s
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
2. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
3. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
4. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
5. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
6. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
7. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
8. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
9. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
10. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
11. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Pa. , July 31, 2014   Auxilium ... fully integrated specialty biopharmaceutical company, today announced that the ... 2014 on Thursday, August 7, 2014 before the opening ... conduct a conference call that day at 8:30 a.m. ... quarter of 2014. The presentation slides to be used ...
(Date:7/31/2014)... Fla. , July 31, 2014 Rock ... today that it has initiated the development of its ... ; and that it has selected Quotient Clinical, The ... Kingdom (UK) to run its early development ... Clinical Trial Application (CTA) by the end of the ...
(Date:7/31/2014)... 2014  Decision Resources Group is launching an extension ... to now include ChinaTrack; the new capabilities track the ... interactive dashboard providing detailed brand-level share tracking and analytics. ... level. Other key capabilities of the new ... addition to end-user surveys of healthcare facilities, ChinaTrack data ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2
... 13 Eli Lilly and Company (NYSE: LLY ... vice president, science and technology, and president, Lilly Research ... Lilly has also announced that Jan M. Lundberg, Ph.D., ... AstraZeneca, is to become his successor. Paul is committed ...
... Millar Instruments, Inc. developer and manufacturer of Mikro-Tip® ... Harvard Apparatus, manufacturer of specialty life science equipment, ... DiGiusto, President of Harvard Apparatus states, "We are ... Instruments to provide comprehensive solutions for physiology research. ...
Cached Medicine Technology:Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor 2Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor 3Millar Instruments and Harvard Apparatus Improve Ability to Provide Customers With Total Physiology Solutions Through Joint Distribution Agreement 2
(Date:8/1/2014)... at the University of California, San Diego School of ... in chili peppers produces chronic activation of a ... a reaction that ultimately reduces the risk of colorectal ... 1, 2014 issue of The Journal of Clinical ... TRPV1, was originally discovered in sensory neurons, where it ...
(Date:8/1/2014)... brain plays a central role in regulating appetite and ... in the brain,s control of food intake and body ... process has been unclear. A new study ... that PPARγ activity in a type of neuron known ... response to high-fat diet. Sabrina Diano and colleagues ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. 1, 2014 (HealthDay News) ... have significantly less endurance than those who weigh less, a new ... were obese, half were of normal weight -- people who were ... Obesity also was associated with less strength, increased discomfort and ... to 65 years of age -- neither improved nor reduced a ...
(Date:8/1/2014)... -- The U.S. Food and Drug Administration announced on ... help fight type 2 diabetes. Jardiance (empagliflozin) ... regimens to control blood sugar levels in the overall ... Office of Drug Evaluation II in the FDA,s Center ... statement. The FDA also recommended that Jardiance be ...
(Date:8/1/2014)... study, researchers at University Hospitals Rainbow Babies & Children,s ... at greater risk for death on a commercial airline ... worldwide between January 2010 and June 2013 and found ... age of 2. , The study was conducted ... of an in-flight pediatric fatality onboard commercial airline flights ...
Breaking Medicine News(10 mins):Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:New research characterizes in-flight pediatric deaths 2
... Mayo is the first organization approved for three specialties ... The American Board of Family Medicine (ABFM), ... American Board of Pediatrics (ABP)—the nation,s three largest physician certifying ... Sponsor of Maintenance of Certification (MOC) activities. Mayo Clinic,s rigorous attention ...
... , SAN DIEGO , Jan. 27 ... that the Company will report its fourth quarter and year-end 2009 ... 2010.  Neurocrine will then host a  live conference call and webcast ... afternoon, February 3, 2010 at 5:00 p.m. Eastern ...
... a leading source of adult stem cells, which are ... the cells is an arduous and often painful process. ... as adipose tissue, may be a promising new source ... and progenitor cells (HSPCs), according to a study ...
... United States has an inefficient and expensive health care system, ... care system detailed in a new study in the ... No. 2). According to the authors of ... Health Care System" from Ben-Gurion University of the Negev (BGU) ...
... of Medicine has been awarded six Department of ... grants for innovative medical research. The grants, totaling ... field of breast cancer. Case Western ... awards and three Idea Awards. The three postdoctoral ...
... few anti-spasticity medications used for children with cerebral palsy ... according to a new review of scientific literature headed ... by a national panel of interdisciplinary experts nationwide. ... release a new practice guideline on effective treatments. Dr. ...
Cached Medicine News:Health News:Mayo Clinic Recognized by Three Certifying Boards for Quality Improvement Activities 2Health News:Mayo Clinic Recognized by Three Certifying Boards for Quality Improvement Activities 3Health News:Mayo Clinic Recognized by Three Certifying Boards for Quality Improvement Activities 4Health News:Mayo Clinic Recognized by Three Certifying Boards for Quality Improvement Activities 5Health News:Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2009 Financial Results 2Health News:Fat tissue may be a source of valuable blood stem cells, study says 2Health News:Fat tissue may be a source of valuable blood stem cells, study says 3Health News:Integrating private insurance with public health would improve US health care -- study 2Health News:Case Western Reserve receives $2.8 million to further breast cancer research 2Health News:Anti-spasticity medications need further research 2
Stainless steel bone clamp....
Designed for proximal femoral elevation in total hip replacement or in other surgery with a similar need for bone manipulation....
To elevate, dissect, scrape and apply traction to bone and soft tissue....
The AV Plus DX pacing lead is designed for use with the St. Jude Medical Affinity VDR pulse generator. This single-lead pacing system provides reliable pacing therapy with the added benefits of AV sy...
Medicine Products: